NCT05580172招募中1 期
A Phase 1 Open Label Dose Ranging Study of Oral RH324 in Advanced Non-Small Cell Lung Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Incidence of Adverse Events Per Common Terminology Criteria for Adverse Events Version 5
研究概览
简要总结
Phase 1 open label dose ranging study of RH324 in advanced non-small cell lung cancer
详细描述
This is a Phase 1 open label dose ranging study to assess the safety and tolerability of oral RH324 in advanced non-small cell lung cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Advanced Non-Small Cell Lung Cancer
- •Measurable Target Lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- •Failed all standard of care including chemotherapy, targeted therapy, and immunotherapy
- •Adults over 18 years
- •Performance status (Eastern Cooperative Oncology Group) less than or equal to 2
- •Life expectancy greater than 2 months
- •Laboratory Values:
- •Hemoglobin greater than or equal to 9; neutrophils greater than 1,000; platelets greater than 50,000 Liver function tests less than or equal to twice upper limit of normal Serum Creatinine less than or equal to 2 Creatinine clearance greater than or equal to 30 mL per minute Hemoglobin A1C less than 7 Normal Thyroid function
- •No history of hyperthyroidism
- •Abstinence from alcohol and supplements
- •Not pregnant, lactating and willing to use birth control throughout study
- •Able to provide consent
- •Positive Emission Tomography/Computer Tomography part of subjects care plan at baseline
排除标准
- •Prior use of Withania somnifera
- •Phenylketonuria
- •Inability to swallow capsules
- •Hypersensitivity to study drug ingredients
- •Unstable medical or surgical condition
- •History of additional cardiac risk factors
- •Requiring drugs that are "strong" inhibitors of cytochrome P450
- •Requiring irradiation
- •Requiring intravenous fluids or hyperalimentation
- •Requiring transfusions, dialysis, or other procedures
- •Active infection
- •Human Immunodeficiency Virus
- •Must exceed washout period of prior treatments
- •Psychiatric, neurological or other reason that precludes subjects ability to participate
研究组 & 干预措施
Dose Level 3
Experimental
RH324
干预措施: RH324 (Drug)
Dose Level 1
Experimental
RH324
干预措施: RH324 (Drug)
Dose Level 2
Experimental
RH324
干预措施: RH324 (Drug)
结局指标
主要结局
Incidence of Adverse Events Per Common Terminology Criteria for Adverse Events Version 5
时间窗: Through Study Completion 28 Days
Percentage of Adverse Events Summarized by Causality and Grade
次要结局
- Percentage of Subjects with a Change from Baseline in Quality of Life(Through Study Completion 28 Days)
- Percentage of Subjects with a Change from Baseline on the Electrocardiogram(Through Study Completion 28 Days)
- Percentage of Subjects with a Change from Baseline on Laboratory Values(Through Study Completion 28 Days)
- Percentage of Subjects with a Change from Baseline on Physical Examination and Vital Signs(Through Study Completion 28 Days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic MetastasesBiliary Tract CancerSecondary Liver CancerLiver MetastasesCarcinoma, HepatocellularNCT04338685Hoffmann-La Roche55
已完成
1 期
A Phase I/II Study of HE3235 in Patients With Prostate CancerProstate CancerNCT00716794Harbor Therapeutics64
已完成
1 期
A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid TumoursAdvanced or Metastatic Solid TumoursNCT01281592Aptose Biosciences Inc.36
已完成
1 期
Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 WeeksMajor Advanced Solid Tumors Other Than ColorectalNCT01405391PharmaMar42
招募中
1 期
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)Relapsed Malignant Solid NeoplasmNCT05865002Aurigene Discovery Technologies Limited50